Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.8
Journals
Genes
Special Issues
Non-coding RNAs on the Tumorigenesis and Metastatic Processes in Cancer
share announcement

Non-coding RNAs on the Tumorigenesis and Metastatic Processes in Cancer

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "RNA".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1837

Special Issue Editors

Dr. Elena Lopez-Jimenez

E-Mail Website
Guest Editor
Inflammation, Repair and Development Department, Imperial College London, London, UK
Interests: gene regulation; epigenetics; non-coding RNAs; cancer; lung diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Eduardo Andrés-León

E-Mail Website
Guest Editor
Instituto de Parasitología y Biomedicina López Neyra (IPBLN-CSIC), Armilla, Spain
Interests: non-coding RNAs; bioinformatics algorithms; data visualization; data integration; cancer data analysis

Special Issue Information

Dear Colleagues,

Non-coding RNAs (ncRNAs) are protein-free RNAs produced by genome transcription. There are approximately 20,000 genes encoded in the human genome, of which 40–90% are estimated to be regulated by miRNA. A variety of RNAs, including small non-coding RNAs (miRNAs/miRs, piRNAs) and long non-coding RNAs (lncRNAs), regulate gene expression at the transcription, post-transcription and epigenetic levels. During the last decade, the discovery of non-coding RNAs’ deregulation in different cancer cells has been the focus of attention for numerous investigations. The emergence of deep sequencing technologies has generated a high volume of public data to further explore the role of ncRNAs, as well as epigenetic modifications (i.e., chromatin remodeling), in the early diagnosis and stratification of patients. Therefore, there is a large amount of interest in the study of non-coding RNAs and epigenetic regulators in order to personalize clinical practice and be able to apply more specific and effective treatments to cancer patients.

Cancer is one of the most prevalent human diseases, affecting millions of people every year worldwide and having a high mortality rate. In recent years, with the development of molecular biology and new technologies, especially genome sequencing, the mechanism of action of lncRNAs in various types of cancer has been gradually revealed, and the study of ncRNAs has been significantly augmented for various cancer types. For instance, lncRNAs are involved in the biological behavior and signaling pathways of metastatic pancreatic cancer, including the cell cycle, apoptosis, autophagy, epithelial–mesenchymal transition (EMT) and cancer stem cells (CSCs). The present review focuses on the characteristics and biological roles of the most described ncRNAs (miRNAs, lncRNAs, piRNAs and circRNAs), with particular emphasis on their implication in cancer.

This Special Issue aims to shed some light on the use of novel candidates for tumor identification and to describe strategies involving non-coding RNAs and epigenetic modifications in cancer, as well as new advances obtained in clinics. Original research manuscripts and comprehensive reviews are welcome.

Dr. Elena Lopez-Jimenez
Dr. Eduardo Andrés-León
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ncRNA
  • cancer
  • miRNAs
  • lncRNAs
  • gene expression regulation
  • epigenetics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 11097 KiB  
Article
Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data
by Janghyun Kim, Young Kim and Bora Lee
Genes 2023, 14(9), 1709; https://doi.org/10.3390/genes14091709 - 28 Aug 2023
Viewed by 1475
Abstract
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or viral infections. Patients with FLC generally have non-specific symptoms, are often diagnosed at a later stage, and experience a higher [...] Read more.
Background: Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that primarily affects adolescents and young adults without prior liver disease or viral infections. Patients with FLC generally have non-specific symptoms, are often diagnosed at a later stage, and experience a higher frequency of metastases compared to patients with other liver cancers. A fusion transcript of DNAJB1 and PRKACA, which can lead to increased activity of PKA and cellular proliferation, has been identified in all FLC patients, but the exact mechanism through which FLC develops remains unclear. In this study, we investigated common lncRNA profiles in various FLC samples using bioinformatics analyses. Methods: We analyzed differentially expressed (DE) lncRNAs from three RNA sequencing datasets. Using lncRNAs and DE mRNAs, we predicted potential lncRNA target genes and performed Gene Ontology (GO) and KEGG analyses with the DE lncRNA target genes. Moreover, we screened for small-molecule compounds that could act as therapeutic targets for FLC. Results: We identified 308 DE lncRNAs from the RNA sequencing datasets. In addition, we performed a trans-target prediction analysis and identified 454 co-expressed pairs in FLC. The GO analysis showed that the lncRNA-related up-regulated mRNAs were enriched in the regulation of protein kinase C signaling and cAMP catabolic processes, while lncRNA-related down-regulated mRNAs were enriched in steroid, retinol, cholesterol, and xenobiotic metabolic processes. The analysis of small-molecule compounds for FLC treatment identified vitexin, chlorthalidone, triamterene, and amiloride, among other compounds. Conclusions: We identified potential therapeutic targets for FLC, including lncRNA target genes as well as small-molecule compounds that could potentially be used as treatments. Our findings could contribute to furthering our understanding of FLC and providing potential avenues for diagnosis and treatment. Full article
(This article belongs to the Special Issue Non-coding RNAs on the Tumorigenesis and Metastatic Processes in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop